RecruitingNCT07207564
Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk
Sponsor
Mayo Clinic
Enrollment
4,500 participants
Start Date
Aug 28, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this research is to better understand how benign breast diseases might lead to breast cancer, focusing on genetic factors and including a diverse range of participants to improve future diagnosis and treatment.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 100 Years
Inclusion Criteria2
- Female patients, ages 18 to 100 years
- Had a benign breast biopsy at Mayo Clinic between 2002-2022
Exclusion Criteria5
- All male patients
- Prior or concomitant diagnosis of BC
- Diagnosis of BC within six months of benign breast disease
- Denial of research authorization
- Concurrent or post-biopsy bilateral prophylactic mastectomy
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07207564
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT059415204 locations
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589836 locations
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT0618475011 locations
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
NCT061953063 locations